Infections related to anti- @entity1722 monoclonal antibodies (mAbs), trastuzumab and pertuzumab, have been reported in clinical trials. It is not yet clear whether these drugs increase an infection risk or not. We performed a systematic review and meta-analysis to assess the risk of @entity281 associated with anti- @entity1722 mAbs. We searched PubMed and the ASCO online database of meeting abstracts up to January 2014 for relevant clinical trials. Eligible studies included randomized controlled trials of trastuzumab or pertuzumab for @entity0 @entity1 that reported adequate safety data for grade 3-4 infection, @entity1398 , @entity1398 , or @entity1431 . The summary incidence, relative risk (RR), and 95  % confidence intervals (CIs) were calculated. A total of 10,094 @entity1 from 13 trials were included. The use of trastuzumab was associated with an increased risk of high-grade infection (RR 1.21, 95  % CI 1.07-1.37, P  =  0.002) and @entity1398 (RR 1.28, 95  % CI 1.08-1.52, P  =  0.004). The incidence of high-grade infection and @entity1398 due to trastuzumab was 8.5  % (95  % CI 4.5-15.4  %) and 12.0  % (95  % CI 8.1-17.4  %), respectively. There was no significant increase in a risk of high-grade @entity1398 or @entity1431 in @entity1 receiving trastuzumab. Treatment with trastuzumab is associated with a significantly higher risk of high-grade infection and @entity1398 . Our findings suggest an importance of close monitoring for any signs of @entity281 in @entity1 treated with trastuzumab.

Infection risk in XXXX @entity1 treated with trastuzumab: a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1722 :: ('2064', 'Gene') :: ['HER2']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
